Not medical advice. Talk to your provider before using any peptide. Full disclaimer
VIP (Vasoactive Intestinal Peptide)
Beginner tier: 200 mcg, daily · clinical practice
Also known as: VIP, aviptadil, Vasoactive Intestinal Polypeptide
Twenty patients. That's the total from the only published VIP trial for CIRS, and every single one showed biomarker normalization. VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide used intranasally as the final step in the Shoemaker protocol for Chronic Inflammatory Response Syndrome. No independent replication exists yet. The Shoemaker clinic reports over 10,000 patients treated since 2008, with consistent drops in TGF-beta 1, C4a, and MMP-9. CIRS patients who have completed all prior protocol steps use VIP to target brain fog, inflammatory marker normalization, and grey matter restoration.
What Is VIP (Vasoactive Intestinal Peptide)?
Twenty-eight amino acids. A plasma half-life of roughly one minute. And a patient community that swears it gave them their brain back. VIP, or Vasoactive Intestinal Peptide (CAS 37221-79-7), is a neuropeptide produced throughout the gut, lungs, and central nervous system. It binds VPAC1 and VPAC2 receptors on immune cells, neurons, and smooth muscle tissue.
In clinical practice, VIP has one primary context: step 12 of Dr. Ritchie Shoemaker's treatment protocol for CIRS (Chronic Inflammatory Response Syndrome) caused by mold and biotoxin exposure. Patients spray it intranasally at 200 to 400 mcg per day, bypassing the rapid plasma degradation that would destroy it in systemic circulation. Rat studies confirmed that roughly 0.1% of an intranasal dose reaches brain tissue through olfactory and trigeminal nerve pathways (Dufes et al.)[1].
Shoemaker's open-label trial of 20 patients (SCIRP, 2013) showed normalization of TGF-beta 1, C4a, MMP-9, and VEGF. His NeuroQuant MRI series reported grey matter volume restoration. The Shoemaker clinic cohort now exceeds 10,000 patients since 2008. Community reports from r/CIRS and biotoxinjourney.com consistently describe brain fog clearing within 2 to 4 weeks.
The honest limitation: all CIRS-specific VIP data comes from Shoemaker's own publications, which are not PubMed-indexed and have not been independently replicated. CIRS itself lacks a formal ICD diagnosis code. Mainstream medicine remains skeptical. Aviptadil (synthetic VIP) does hold FDA orphan drug designation for pulmonary arterial hypertension, and COVID-19 respiratory failure trials were published in 2022 and 2023.
How VIP (Vasoactive Intestinal Peptide) Works
VIP binds two G-protein-coupled receptors, VPAC1 and VPAC2, scattered across immune cells, neurons, smooth muscle, and epithelial tissue. Receptor activation triggers adenylyl cyclase, which raises intracellular cAMP. That cAMP increase sets off an anti-inflammatory cascade with several downstream effects.
First, NF-kB activation gets suppressed. That means lower production of TNF-alpha, IL-6, and IL-12. Second, VIP shifts the T-helper balance away from Th1 and Th17 dominance toward regulatory T-cell expansion. Treg cells are the immune system's off switch for runaway inflammation; in CIRS, that switch is stuck.
In blood vessels, VIP relaxes smooth muscle. It's a potent vasodilator, roughly 50 to 100 times more potent than acetylcholine on a molar basis (Domschke et al.)[2]. That vasodilation reduces pulmonary artery pressure, which matters for CIRS patients with exercise intolerance.
In the brain, VIP protects neurons from oxidative damage and excitotoxicity. The intranasal route is what makes this possible. Sprayed into the nose, VIP reaches the CNS directly through olfactory and trigeminal nerve pathways. This bypasses the one-minute plasma half-life that would destroy it in systemic circulation. Dufes and colleagues confirmed this delivery pathway in rat models [1], showing about 0.1% of the intranasal dose reaching brain tissue, with a CNS Tmax of approximately 30 minutes.
VIP (Vasoactive Intestinal Peptide) Benefits
- VIP benefits center on immune normalization, neuroprotection, and inflammatory biomarker correction in CIRS patients.
- Normalizes four key CIRS biomarkers (TGF-beta 1, C4a, MMP-9, VEGF) in Shoemaker's published 20-patient trial; the clinic reports consistent results across 10,000+ patients since 2008.
- Restores grey matter nuclear volume in the brain, documented on NeuroQuant MRI in Shoemaker's imaging series (2017).
- Brain fog resolution is the most frequently reported early benefit, with community reports describing clarity returning within 2 to 4 weeks of intranasal dosing.
- Improves pulmonary artery pressure and exercise tolerance through vasodilation of smooth muscle tissue.
- Neuroprotective against oxidative stress and excitotoxicity, with receptor-mediated cAMP signaling in central nervous system neurons.
- Shifts T-helper balance from Th1/Th17 dominance to regulatory T-cell expansion, re-engaging the immune system's ability to self-regulate.
VIP (Vasoactive Intestinal Peptide): Science vs Community Consensus
Intranasal VIP normalizes CIRS inflammatory biomarkers (TGF-beta 1, C4a, MMP-9, VEGF) and restores grey matter volume in Shoemaker protocol patients.
Read the evidence (key study, limitations)
Evidence is exclusively from Shoemaker's own unindexed case series: no independent RCTs exist. Aviptadil (synthetic VIP) has FDA orphan drug designation for PAH; COVID-19 respiratory failure trials published 2022 and 2023.
Shoemaker et al. 2013 (SCIRP, not PubMed-indexed): open-label 20-patient trial; RNA-Seq transcriptome study (ESMED 2022); NeuroQuant grey matter restoration series (Shoemaker 2017)
All CIRS-specific VIP trials are Shoemaker's own publications in SCIRP: not PubMed-indexed and not independently replicated. CIRS is not a recognized ICD diagnosis in mainstream medicine. The 15,071 PubMed VIP papers cover basic science and non-CIRS indications, not the Shoemaker protocol. Shoemaker clinic reports 10,000+ patients since 2008, but no independent registry or audit exists.
Highly valued as the final step of the Shoemaker CIRS protocol.
Read the reports (what users report 5, common issues 5)
Patients who have completed all prior steps consistently report brain fog resolution, biomarker normalization, improved energy, and quality of life recovery. Starting VIP before completing steps 1–10 (especially MARCoNS eradication) is the most common and costly error.
- Brain fog resolution and cognitive clarity (weeks 2–4)
- Inflammatory biomarker normalization (C4a, TGF-beta 1, MMP-9, VEGF)
- Grey matter volume restoration on NeuroQuant MRI
- Improved exercise tolerance and energy
- Better sleep quality
- Starting too early (before steps 1–10 complete): wasted money, no benefit
- Transient initiation worsening: dysphoria, "toxic feelings," palpitations in ~10–15% of patients
- High cost: $189–$399/month for compounded pharmaceutical-grade
- Relapse on re-exposure to water-damaged buildings; VIP cannot prevent re-exposure-driven recurrence
- Step number confusion in community materials (noted as step 11 in some sources; Shoemaker's own protocol states step 12 of 12)
Within the CIRS framework, Shoemaker's clinical series and the patient community converge on the same protocol, dosing range (200–400 mcg/day), prerequisites, and expected biomarker outcomes. Mainstream medicine does not recognize CIRS as a formal diagnosis: this creates a broader disconnect with general scientific consensus, but that external disagreement does not affect the internal alignment between Shoemaker's data and patient community reports.
VIP (Vasoactive Intestinal Peptide) Dosage Guide
Your first VIP vial comes as a nasal spray, not an injectable. Standard compounding: 5 mg vial reconstituted in 10 mL bacteriostatic water gives 500 mcg/mL. Each spray actuation delivers 0.1 mL, which equals 50 mcg per spray. Four sprays per dose means 200 mcg total.
The biggest mistake people make is starting VIP too early. MARCoNS must be eradicated and confirmed negative on retest. VCS must be passing. If you skip those prerequisites, you'll spend $189 to $399 per month on a peptide that won't work because the underlying inflammation source is still active.
Alternate nostrils with each spray (two sprays per nostril per dose). Morning dosing before food is standard. If you're sensitive, ask your prescriber about a 1:10 or 1:100 dilution for the first week; that dilution step makes initiation worsening much less likely.
Get fasting lipase drawn before you start. No exceptions. Monthly lipase for three months after that.
Cycling
No scheduled off period.
In the Shoemaker protocol, VIP is often continued for 1-3 months until lab markers (TGF-beta, C4a, VEGF, MMP-9) normalize. Some patients use VIP intermittently for maintenance.
VIP treatment in CIRS continues until biomarkers normalize (TGF-beta 1, C4a, MMP-9, VEGF) and VCS improves: typically 8–12 weeks. Continuation beyond that is individually determined by biomarker response. Cycling is driven by safety monitoring checkpoints (lipase) and therapeutic endpoints rather than receptor desensitization. Intermittent maintenance use is common in patients with ongoing re-exposure risk.
- Biomarker normalization: TGF-beta 1 <2,380 pg/mL, C4a <2,830 ng/mL, MMP-9 <332 ng/mL, VEGF 31–86 pg/mL
- VCS test passing and showing progressive improvement from baseline
- Symptomatic resolution: brain fog cleared, exercise tolerance restored, fatigue reduced
- Lipase remaining normal at all monitoring timepoints throughout treatment
Or use the universal Peptide Calculator for any peptide.
VIP (Vasoactive Intestinal Peptide) Protocols by Goal
Expected: TGF-beta 1 <2,380 pg/mL, C4a <2,830 ng/mL, MMP-9 <332 ng/mL, VEGF 31–86 pg/mL. Passing VCS. Cognitive clarity and grey matter volume restoration on NeuroQuant MRI.
Monitor: Fasting lipase required before start (must be normal). Monthly lipase × 3 months, then quarterly. TGF-beta 1, C4a, MMP-9, VEGF at baseline and every 4–8 weeks. VCS testing monthly. Stop VIP immediately if lipase elevates.
How to Use VIP (Vasoactive Intestinal Peptide)
- 1Step 1
Confirm prerequisites are met: MARCoNS eradicated (negative retest), VCS passing, fasting lipase normal (<60 U/L), and Shoemaker protocol steps 1 through 11 completed.
- 2Step 2
Obtain VIP nasal spray from a licensed 503A compounding pharmacy. Standard concentration: 5 mg vial in 10 mL bacteriostatic water = 500 mcg/mL. Each actuation delivers 0.1 mL = 50 mcg per spray.
- 3Step 3
Prime the spray bottle per pharmacy instructions before first use.
- 4Administer 4 sprays total per dose (200 mcg)
Alternate nostrils: 2 sprays in the left nostril, 2 sprays in the right. Tilt the head slightly forward.
- 5Dose timing: morning, before food
If titrating to twice daily, add a second dose in the early afternoon.
- 6Step 6
Beginner schedule: 200 mcg once daily (4 sprays) for weeks 1 to 2. Moderate: 200 mcg twice daily (8 sprays total, 400 mcg/day) starting week 3 if tolerated. Aggressive: 400 mcg once daily (8 sprays) is the Shoemaker protocol maximum; do not exceed 400 mcg/day.
- 7Step 7
Sensitive patients: dilute VIP 1:10 or 1:100 during week 1 to reduce initiation worsening risk.
- 8Step 8
Storage: refrigerate at 2 to 8 degrees C (36 to 46 degrees F) at all times. Reconstituted vial is stable for 30 days. Discard if cloudy, discolored, or left at room temperature.
- 9Step 9
Monitoring: fasting lipase monthly for the first 3 months, then quarterly. TGF-beta 1, C4a, MMP-9, and VEGF every 4 to 8 weeks. VCS testing monthly.
Alternative Routes
IV aviptadil doses studied for PAH/ARDS are orders of magnitude different from intranasal CIRS dosing; clinical contexts not interchangeable.
Aviptadil is synthetic VIP. IV plasma half-life ~1 minute: even shorter effective exposure than intranasal CNS delivery via olfactory/trigeminal pathways. IV is not a viable or practiced CIRS route. Intranasal is the only route used in Shoemaker's published CIRS protocol.
VIP (Vasoactive Intestinal Peptide) Stacking Protocols
Works With
Complementary T-cell and immune modulation. Some CIRS practitioners add TA1 for patients with concurrent immune deficiency or persistent infections. No clinical trial data on VIP + TA1 combination.
Adjunct NF-kB suppression for CIRS patients with prominent gut inflammation. KPV is occasionally added during earlier Shoemaker steps and may continue into the VIP phase. No formal protocol exists.
Avoid
VIP is a potent vasodilator (50–100× more potent than acetylcholine on a molar basis). Additive hypotension risk: significant in CIRS patients who may already have orthostatic intolerance.
Both VIP and PDE5 inhibitors cause vasodilation via overlapping cGMP/cAMP pathways. Compounding hypotension risk.
Do not combineOverlapping immune modulation. May blunt or unpredictably alter VIP's immune-normalizing effects. Corticosteroids also suppress endogenous VIP signaling.
Estimated Cost
Pricing updated 2026-04-09
VIP (Vasoactive Intestinal Peptide) Side Effects
Lipase elevation is the safety signal that matters most. In Shoemaker's cohort of 600 patients with monitoring data, 4 developed raised lipase levels during VIP treatment, an incidence of roughly 0.7%. The protocol requires an immediate stop if lipase rises above normal (<60 U/L). This is a non-negotiable safety checkpoint, not a suggestion. Fasting lipase must be normal before starting, then checked monthly for three months, then quarterly.
Transient initiation worsening affects approximately 10 to 15% of patients during the first week. Community reports describe it as dysphoria, a "toxic feeling," or palpitations. The Shoemaker clinic recommends diluting VIP 1:10 or 1:100 for sensitive patients during week one. These symptoms typically self-resolve within 3 to 7 days. Reducing concentration rather than stopping is the standard approach.
Mild nasal irritation and congestion are common with intranasal delivery. Some patients report transient headache in the first two weeks. Both are expected and usually resolve without intervention.
Diarrhea and nausea can occur but are uncommon at standard intranasal doses (200 to 400 mcg per day). These are more typical of intravenous VIP, where systemic exposure is much higher.
Hypotension is a real risk, though rare at intranasal doses. VIP is 50 to 100 times more potent than acetylcholine as a vasodilator (Domschke et al.)[2]. Patients on antihypertensives or phosphodiesterase inhibitors (sildenafil, tadalafil) face additive risk. Blood pressure monitoring during initiation is reasonable for anyone with orthostatic intolerance.
Contraindications are strict. VIP is contraindicated in pregnancy and breastfeeding. It should not be used in patients with VIP-secreting tumors (VIPomas), severe hypotension, or active MARCoNS infection. A failing VCS test means VIP should not be started, as it indicates unresolved biotoxin burden. Starting VIP before completing Shoemaker protocol steps 1 through 11 is the single most common and costly error the community reports.
When to stop: immediately if lipase elevates. If no biomarker improvement appears after 12 weeks, the most likely cause is ongoing biotoxin re-exposure or incomplete prior treatment steps.
Common Issues & Solutions
No response after 8–12 weeks: Primary cause is ongoing biotoxin re-exposure: VIP cannot override active mold re-exposure. Secondary: incomplete prior steps (MARCoNS not eradicated, VCS still failing, or prior inflammatory markers not adequately reduced before starting VIP).
Dysphoria, "toxic feelings," or palpitations on initiation: Dilute VIP 1:10 or 1:100 in the spray bottle. Symptoms typically self-resolve within 3–7 days. Do not discontinue: reduce concentration and titrate up slowly.
Lipase elevation on monitoring labs: Stop VIP immediately and contact prescriber. Protocol-mandated safety stop. ~0.7% incidence (4/600 in Shoemaker cohort). Lipase typically normalizes after discontinuation.
Biomarkers partially improving but VEGF remains low: Most common in patients recently departed from water-damaged buildings. Environmental remediation must be confirmed: VEGF cannot fully normalize with ongoing low-level re-exposure.
Storage lapse / warm vial received: Discard immediately. VIP degrades rapidly at room temperature. Intranasal VIP for human use comes from licensed 503A compounding pharmacies (prescription required). Research-grade products are not appropriate for human intranasal use.
Ask AI about this page
Ask AI for a second opinion on VIP (Vasoactive Intestinal Peptide) dosing and side effects
Contraindications
- Pregnancy or breastfeeding
- Active VIP-secreting tumors (VIPomas) or suspected VIPoma
- Severe hypotension or orthostatic intolerance
- Active MARCoNS infection (must eradicate before starting VIP per Shoemaker protocol)
- Failing Visual Contrast Sensitivity (VCS) test (indicates unresolved biotoxin burden)
- Known hypersensitivity to VIP or formulation excipients
Drug Interactions
- Antihypertensives: VIP causes vasodilation and may potentiate blood pressure lowering
- Anticoagulants (warfarin, heparin): use caution due to VIP's vasodilatory effects
- Corticosteroids and immunosuppressants: overlapping immune-modulating effects may alter therapeutic response
- Phosphodiesterase inhibitors (sildenafil, tadalafil): additive vasodilation risk
Product Quality
Pharmaceutical-grade VIP is available only through licensed 503A compounding pharmacies, by prescription. Research-grade or "for research only" products do not meet pharmaceutical quality standards for human use. Rapid degradation at room temperature makes cold-chain integrity critical. No FDA-approved intranasal VIP formulation exists: no standardized quality benchmark outside of USP compounding standards.
- Human use requires pharmaceutical-grade sterility and concentration accuracy, which research-grade products lack; compounded VIP requires a prescription.
- Confirm cold-chain shipping (refrigerated or with ice pack); refrigerate immediately upon receipt (2–8°C).
- Inspect each vial: discard if cloudy, discolored, or seal integrity is compromised.
- Check compounding pharmacy accreditation (PCAB or state board equivalent).
- Verify concentration with the pharmacy: standard is 50 mcg/spray = 500 mcg/mL with 0.1 mL actuations in a 10 mL vial.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Fasting lipase | Required before starting (must be normal); monthly × 3 months; then quarterly | Must be normal (<60 U/L typical) before starting; stop VIP immediately if elevated during treatment |
| TGF-beta 1 | Baseline, then every 4–8 weeks | <2,380 pg/mL (Shoemaker normal range) |
| C4a (complement) | Baseline, then every 4–8 weeks | <2,830 ng/mL |
| MMP-9 (matrix metalloproteinase-9) | Baseline, then every 4–8 weeks | <332 ng/mL |
| VEGF (vascular endothelial growth factor) | Baseline, then every 4–8 weeks | 31–86 pg/mL |
| Visual Contrast Sensitivity (VCS) test | Must pass before starting VIP; monthly during treatment | Not listed |
Lipase elevation in ~0.7% of patients (4/600 in Shoemaker cohort).
Primary biomarker of CIRS severity and VIP treatment response. Elevated at baseline; should trend downward.
Key marker of innate immune dysregulation in CIRS. Should normalize with effective VIP treatment.
Surrogate marker for systemic inflammation in CIRS. Should decrease with effective VIP treatment.
Characteristically LOW in CIRS: VEGF deficiency contributes to exercise intolerance and poor tissue perfusion. VIP should restore levels to normal range.
Shoemaker protocol prerequisite: failing VCS means VIP should not be initiated. Improving VCS during treatment confirms response and absence of ongoing biotoxin re-exposure.
VIP (Vasoactive Intestinal Peptide) Before and After
Initial intranasal dosing begins. Some patients notice mild nasal irritation. No significant clinical changes expected yet.
Early improvements in energy, mental clarity, and exercise tolerance. Inflammatory markers may begin to trend downward.
Measurable reductions in TGF-beta 1, C4a, and MMP-9 in responding patients. VEGF levels begin to normalize. Improved sleep and reduced brain fog.
Significant normalization of inflammatory markers in most responders. NeuroQuant MRI may show grey matter improvements. Many patients reach treatment goals.
Maintenance phase or tapering based on lab results. Retreatment may be needed if re-exposure occurs.
What to Expect
Days 1 through 7 (Initiation): VIP binds VPAC1 and VPAC2 receptors in nasal epithelium and reaches the CNS through olfactory and trigeminal pathways. Early cAMP upregulation begins. Most patients notice nothing perceptible. Around 10 to 15% report transient dysphoria, palpitations, or a "toxic feeling" that resolves within 3 to 7 days. Diluting to 1:10 or 1:100 concentration handles this for sensitive patients.
Weeks 2 through 4 (Early Response): Inflammatory cytokine balance starts shifting. Treg expansion begins, and early reductions in TGF-beta 1 and C4a appear in responders. Brain fog lifting is the most commonly reported sign during this window. Energy picks up. Sleep quality improves. Mild nasal irritation may persist but is manageable.
Weeks 4 through 8 (Biomarker Normalization): Lab work starts confirming what patients feel. Measurable drops in TGF-beta 1, C4a, and MMP-9. VEGF levels begin recovering. Shoemaker's RNA-Seq data from this window shows a shift toward an anti-inflammatory metabolic state. Community members run follow-up labs and post results showing markers trending into normal ranges. Exercise tolerance improves. Joint and muscle aches ease.
Weeks 8 through 12 (Grey Matter and Full Response): Shoemaker's NeuroQuant MRI series documented grey matter nuclear volume restoration at this stage. Most biomarkers reach normal ranges in responders. Patients in the CIRS community describe this phase as "getting their brain back." Quality of life improvements become clear and sustained.
Month 3 and beyond (Maintenance): Sustained normalization holds if biotoxin re-exposure is avoided. Most patients taper or stop after biomarkers normalize. Some continue intermittent dosing for maintenance if ongoing exposure risk exists. The strongest community consensus: VIP cannot prevent relapse from re-exposure to water-damaged buildings.
Detailed Timeline: Science vs Community
VIP binds VPAC1/VPAC2 receptors in nasal epithelium and reaches CNS via olfactory/trigeminal pathways. Early cAMP upregulation and NF-kB suppression begin. No measurable biomarker change expected this early.
Most patients report no perceptible change. Approximately 10–15% report transient dysphoria, "toxic feeling," or palpitations: the most discussed initiation experience in the CIRS community.
Progressive shift in inflammatory cytokine balance. Treg expansion begins. Early TGF-beta 1 and C4a reduction in responding patients.
Brain fog lifting is the most frequently reported early sign. Energy improvements. Sleep quality begins to improve.
Measurable reductions in TGF-beta 1, C4a, MMP-9. VEGF levels begin recovering. Shoemaker's RNA-Seq data shows shift toward anti-inflammatory metabolic state and innate immune normalization.
Patients run follow-up labs and report markers trending toward normal ranges. Improved exercise tolerance. Reduced joint and muscle aches. Clearer thinking.
Shoemaker NeuroQuant MRI series shows grey matter nuclear volume restoration in responding patients. Most biomarkers normalized by week 12 in responders.
Patients describe this as "getting their brain back." Significant quality of life improvement. Some continue VIP beyond 12 weeks for full grey matter restoration.
Sustained normalization if biotoxin re-exposure is avoided. Re-exposure causes rapid relapse: VIP cannot prevent re-exposure-driven CIRS recurrence.
Most patients taper or stop after biomarker normalization. Intermittent use for symptom management in patients with unavoidable exposure risk. Strongest community message: "Don't waste your money if you're still in a moldy building."
Pharmacokinetics
Source: Domschke et al. 1978: ~1 min plasma half-life via IV; intranasal delivery bypasses rapid plasma degradation via direct CNS uptake
Pharmacokinetics: Active Dose Over Time
t½ = ~1-2 minutes (plasma)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is VIP (Vasoactive Intestinal Peptide) Legal?
VIP (Vasoactive Intestinal Peptide) does not have FDA approval for intranasal use in CIRS. It is classified as research-only for this application. Aviptadil, the synthetic form of VIP, holds FDA orphan drug designation for pulmonary arterial hypertension and received Fast Track designation for that indication. No FDA-approved intranasal VIP product exists.
Intranasal VIP for CIRS is compounded under 503A pharmacy regulations on a per-patient prescription basis. It requires a valid prescription from a licensed practitioner. Compounding pharmacies producing VIP must comply with USP <797> sterility standards.
Athletes should note that VIP's regulatory status with WADA has not been explicitly addressed. Consult a sports medicine physician before use if subject to anti-doping testing.
This content is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider VIP (Vasoactive Intestinal Peptide)
- CIRS (Chronic Inflammatory Response Syndrome) patients who have completed Shoemaker protocol steps 1-10
- Individuals with confirmed mold/biotoxin illness and persistently elevated inflammatory markers
- Patients with elevated TGF-beta 1, C4a, MMP-9, or low VEGF after initial CIRS treatment
- Adults with CIRS-related cognitive impairment or grey matter atrophy on NeuroQuant MRI
- Patients with CIRS-associated pulmonary hypertension or exercise intolerance
Related Peptides
What Changed for VIP (Vasoactive Intestinal Peptide)
- Evidence
Corrected Oct 20, 2026: VIP's research stage is phase 3, not 1; IV aviptadil (synthetic VIP) had a published phase 3 (TESICO), per PubMed (PMID 37348524).
Before: Phase 1 After: Phase 3 (TESICO, IV aviptadil in COVID-19 respiratory failure, PMID 37348524)
What this does not mean: No new study was published, and the dose tiers are unchanged. TESICO gave IV aviptadil for COVID-19 respiratory failure and stopped it for futility. The intranasal CIRS use on this page rests on one 20-patient open-label study.
Source: Lancet Respir Med 2023, Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (Brown et al.; registered as phase 3, NCT04843761) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 20264 Citations
References
- [1]Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats (Dufes et al., 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects (Domschke et al., 1978) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) (Shoemaker et al., Health 2013) (opens in a new tab)Review
- Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration (Pharmazie 2013) (opens in a new tab)PubMed 23444784PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is VIP (Vasoactive Intestinal Peptide)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Low. Community mentions on Reddit: Low-moderate in r/CIRS context. Open r/CIRS (members unknown: not scrapable) (opens in a new tab).
15,071 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.